(b) Trade and other payables 2024 2023 US$m US$m Trade payables 867 820 Accruals and other payables 2,478 2,127 Carrying amount of current trade and other payables 3,345 2,947 Accruals and other payables 230 251 Contingent consideration associated with business combinations (Note 10) 220 242 Carrying amount of other non-current liabilities 450 493 Trade payables, accruals and other payables represents the notional amounts owed to suppliers for goods and services provided to the Group prior to the end of the financial year that are unpaid. Trade and other payables are non-interest bearing and have various repayment terms but are usually paid within 30 to 60 days of recognition. Note 14: Provisions Provisions are recognised when the Group has a present obligation, it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made of the obligation. Provisions are not recognised for future operating losses. Provisions recognised reflect our best estimate of the expenditure required to settle the present obligation at the reporting date. Where the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows to settle the obligation at a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the obligation. Provisions for employee benefits includes the liability for leave entitlements, related on costs and restructuring costs where required. Other provisions include provisions for asset retirement obligations and onerous contracts. Other provisions also include the estimated fair value of potential contingent liabilities assumed on business acquisition date of Vifor Pharma relating to various claims and disputes with third parties in each case where there is a possible future financial exposure, and involve an assessment of the likelihood of several scenarios in relation to those matters. During the year ended 30 June 2024, CSL Vifor settled some legacy Vifor Pharma disputes. These settlements were provided for as at 30 June 2023 as part of the purchase price accounting for the Vifor Pharma acquisition. Management expects the settlement payments to be made by the end of the next financial year. As such, these amounts are included in the reclassifications to current provisions at 30 June 2024. Employee benefits Other Total 2024 2023 2024 2023 2024 2023 US$m US$m US$m US$m US$m US$m Current Carrying amount at the start of the year 246 172 64 10 310 182 Utilised/transfers (103) (65) (72) (9) (175) (74) Reclassified from non-current — — 273 — 273 — Additions 69 126 — 4 69 130 Acquisition of CSL Vifor — 11 — 67 — 78 Currency translation differences 1 2 (3) (8) (2) (6) Carrying amount at the end of the year 213 246 262 64 475 310 Non-current Carrying amount at the start of the year 60 41 407 61 467 102 Utilised/transfers (14) (2) 11 (1) (3) (3) Reclassified to current — — (273) — (273) — Additions 6 6 — 1 6 7 Acquisition of CSL Vifor — 9 — 347 — 356 Currency translation differences — 6 (11) (1) (11) 5 Carrying amount at the end of the year 52 60 134 407 186 467 135
RkJQdWJsaXNoZXIy MjE2NDg3